Call to Action: How to Tackle Emerging Nosocomial Fungal Infections

Michail S Lionakis; Tobias M Hohl

doi:10.1016/j.chom.2020.04.011

Call to Action: How to Tackle Emerging Nosocomial Fungal Infections

Cell Host Microbe. 2020 Jun 10;27(6):859-862. doi: 10.1016/j.chom.2020.04.011.

Authors

Michail S Lionakis¹, Tobias M Hohl²

Affiliations

¹ Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: lionakism@niaid.nih.gov.
² Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hohlt@mskcc.org.

Abstract

Nosocomial fungal infections require a robust scientific response to complement antifungal development and the implementation of infection control measures. This Commentary discusses how a parallel effort to address fungal pathogenesis and antifungal immunity, the mycobiota and colonization resistance, and risk factors is essential to reduce the toll of these infections.

Publication types

Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural

MeSH terms

Antifungal Agents / immunology*
Antifungal Agents / therapeutic use
Cross Infection / drug therapy
Cross Infection / immunology
Cross Infection / microbiology*
Fungi / pathogenicity*
Humans
Immunity*
Mycobiome / drug effects
Mycobiome / immunology
Mycoses / microbiology
Risk Factors

Substances

Antifungal Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding